Clinical trials
HER2 Positive Breast Carcinoma clinical trials
Below are recruiting her2 positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 282 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT07615751RecruitingPhase 3
New drug combination for advanced HER2-positive breast cancer
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07613151Recruiting
Lobular breast cancer with low hormone receptors
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
PadovaAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT05891561RecruitingPhase 2
Short antibody treatment after surgery for early HER2+ breast cancer
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT04985266RecruitingPhase 2
Watch blood DNA for early breast cancer return, then add palbociclib
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
AngersAges 18 years+ - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Jonesboro, ArkansasAges 18 years+ - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06276868RecruitingPhase 2
Darsilide plus hormone therapy and double antibody for breast cancer
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Henan, HenanAges 18–70 - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07506876RecruitingPhase 2
Combined hormone and chemo before surgery for HER2+ breast cancer
This trial tests combining hormone therapy with chemotherapy and targeted therapy before surgery for a type of breast cancer that is both hormone-receptor-positive (HR+) and HER2-positive. The goal is to see if this combination works better than standard treatment.
Gresham, OregonAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07483307RecruitingPhase 2
Hormone therapy before surgery for lobular breast cancer
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
Basking Ridge, New JerseyAges 50 years+ - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT07402473RecruitingPhase 2
Optimizing treatment before surgery for HER2-positive breast cancer
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Elizabeth, New JerseyAges 18–90 - NCT06832904RecruitingPhase 2
Chemo plus two targeted drugs before surgery for HER2+ breast cancer
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
HangzhouAges 18–75 - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT05020860RecruitingPhase 2
Study how early breast cancer responds on imaging and under a microscope
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Houston, TexasAges 18 years+ - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT06035679Recruiting
Combination therapy before surgery for HER2-positive breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive breast carcinoma?
- Yes. Clin2 currently lists 282 recruiting her2 positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.